Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone
Capricor Therapeutics (CAPR) is drawing investor attention with new clinical data for its Duchenne muscular dystrophy therapy, deramiocel, and an upcoming PDUFA decision date. The stock has seen significant momentum, with a 24.36% 30-day return and strong multi-year gains. Despite a current valuation of US$1.85 billion and a recent share price of US$32.11, Simply Wall St's analysis suggests a fair value of $50.80 per share, indicating it is undervalued based on aggressive growth and profitability assumptions, although risks like reliance on Deramiocel and rising R&D costs remain.
Precision Trading with Capricor Therapeutics Inc. (CAPR) Risk Zones
This article analyzes Capricor Therapeutics Inc. (CAPR) using AI models to identify trading risk zones. It highlights a potential short setup with a significant risk-reward ratio, outlining institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis suggests positive near-term sentiment but a weak mid-term bias within a long-term strong outlook for CAPR.
Capricor Therapeutics (CAPR) Is Up 7.2% After HOPE-3 Data And PDUFA Update Has The Bull Case Changed?
Capricor Therapeutics (CAPR) saw its stock rise by 7.2% following the release of new HOPE-3 data and an update on its August 22, 2026 PDUFA decision for its Duchenne muscular dystrophy cell therapy, deramiocel. Despite a larger-than-expected Q4 2025 loss and a CFO stock sale, investor focus remains on the potential approval of deramiocel. The article discusses how these developments could impact the company's investment narrative, emphasizing the need for deramiocel to clear regulatory hurdles before significant cash burn or competition become major issues.
Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone
Capricor Therapeutics (CAPR) has gained investor attention due to new clinical data for its Duchenne muscular dystrophy therapy, deramiocel, and a confirmed PDUFA decision date. The company, currently valued at US$1.85 billion with a share price of US$32.11, is considered 36.8% undervalued by analysts, who set a fair value of $50.80 per share. This valuation hinges on assumptions of rapid revenue growth, profitability, and future earnings multiples, though risks like reliance on Deramiocel and rising R&D costs remain.
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells 7,529 Shares of Stock
A director at Capricor Therapeutics (NASDAQ:CAPR), Karimah Es Sabar, sold 7,529 shares of the company's stock on April 2nd at $32.00 per share, totaling $240,928. This transaction, executed under a Rule 10b5-1 plan, reduced her direct ownership in the company by 50%. Combined with earlier sales on April 1st and March 31st, Es Sabar sold a total of 122,529 shares for approximately $3.76 million.
Capricor Therapeutics (CAPR) director sells 7,529 exercised shares
A director at Capricor Therapeutics (CAPR), Karimah Es Sabar, exercised stock options to acquire 7,529 shares at $3.18 per share and subsequently sold all of them for $32.00 per share. These transactions, valued at $240,928, were conducted under a pre-arranged Rule 10b5-1 trading plan established in December 2025. Following the sale, the director holds no Common Stock directly.
Capricor Therapeutics director sells $3.5m in shares
Capricor Therapeutics director Sabar Karimah Es sold 115,000 shares of common stock for approximately $3.5 million in early April 2026, following the exercise of options to acquire these shares. The sales were made under a prearranged trading plan and occurred while the stock was trading significantly higher than the exercise price. Despite the sales, InvestingPro analysis suggests the stock remains undervalued, and the company recently reported Q4 2025 earnings with a wider-than-expected loss but maintains an "Overweight" rating from Cantor Fitzgerald due to strategic initiatives and clinical advancements.
CAPR SEC Filings - Capricor Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Capricor Therapeutics (CAPR) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. Stock Titan offers access to these official regulatory documents, enhanced with AI-powered summaries and sentiment analysis. The article highlights that these filings are crucial for understanding the company's financial condition, clinical milestones, and material corporate events.
Option exercise and 10b5-1 sales reported by CAPR (NASDAQ: CAPR)
A recent SEC Form 144 filing indicates a proposed sale of 7,529 shares of Common Stock for CAPR (Capricor Therapeutics, Inc.) on April 2, 2026, stemming from the exercise of stock options for cash. Additionally, the filing reports two 10b5-1 sales by Karimah Es Sabar: 53,735 shares on April 1, 2026, yielding $1,667,225.10, and 61,265 shares on March 31, 2026, generating $1,848,242.52. This filing provides routine administrative disclosures regarding insider liquidity transactions.
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock
Capricor Therapeutics Director Karimah Es Sabar sold 53,735 shares for over $1.6 million on April 1st, following a previous sale of 61,265 shares for over $1.8 million on March 31st. Despite these insider sales, analysts maintain a "Moderate Buy" rating for CAPR with an average price target of $46.09, and several firms have recently increased their price targets. The company reported a quarterly EPS miss of ($0.62) against consensus estimates of ($0.51).
Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock
Karimah Es Sabar, a Director at Capricor Therapeutics (NASDAQ:CAPR), sold a total of 115,000 shares across two transactions on March 31st and April 1st, generating approximately $3.52 million. Capricor Therapeutics is currently trading around $31.62 with a market capitalization of $1.82 billion, and analysts hold a "Moderate Buy" rating with an average target price of $46.09, despite the company missing its Q1 EPS estimates.
Capricor Therapeutics(CAPR.US) Director Sells US$3.52 Million in Common Stock
A director at Capricor Therapeutics (CAPR.US) recently sold 750,000 shares of common stock for a total of $3.52 million. The sale was executed across multiple transactions at an average price of $4.69 per share. Following this transaction, the director now directly owns 1.15 million shares of the company.
Capricor (NASDAQ: CAPR) EVP sells 25K shares after option exercises
Karen Krasney, EVP and General Counsel of Capricor Therapeutics (NASDAQ: CAPR), reported exercising stock options for 25,000 shares and subsequently selling all 25,000 shares at a weighted average price of $30.1174 per share. The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these sales, Krasney directly holds 30,547 shares of CAPRICOR common stock.
Director at Capricor (NASDAQ: CAPR) sells 115,000 shares via 10b5-1 plan
Capricor Therapeutics director Karimah Es Sabar exercised stock options for 115,000 shares at $4.86 per share and subsequently sold all 115,000 shares in open-market transactions on March 31 and April 1, 2026, at weighted average prices of $30.1680 and $31.0268. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, no shares from the exercised options remained held.
Capricor Therapeutics director sells $3.5m in shares
A director at Capricor Therapeutics recently sold 115,000 shares for approximately $3.5 million, while also exercising options worth $558,900. Despite a significant stock price increase, InvestingPro analysis indicates the stock may still be undervalued. Cantor Fitzgerald maintained an "Overweight" rating with a $62 price target, highlighting the company's PDUFA date for deramiocel and new HOPE-3 data.
Capricor Therapeutics Stock Rises Above 50-Day Average
Capricor Therapeutics (NASDAQ:CAPR) stock has surpassed its 50-day moving average, signaling increased investor confidence in its cell and exosome-based therapies. Analysts like Piper Sandler and HC Wainwright have reiterated "overweight" or "buy" ratings with price targets of $58 and $60, respectively. The company, based in Beverly Hills, specializes in treatments for cardiovascular and rare diseases, and its performance above this key technical indicator is seen as a positive sign by market observers.
[144] CAPRICOR THERAPEUTICS, INC. SEC Filing
This article details an SEC Form 144 filing by Capricor Therapeutics, Inc. (CAPR), indicating a proposed sale of 75,000 shares of common stock with an aggregate market value of $2,082,750. The transaction involves the exercise of stock options by an insider, with the shares to be sold through Morgan Stanley Smith Barney LLC on NASDAQ. The filing provides transparent information about the securities acquisition and the planned sale.
[144] CAPRICOR THERAPEUTICS, INC. SEC Filing
This article reports on Capricor Therapeutics, Inc.'s SEC Form 144 filing, dated March 31, 2026, which details a proposed sale of 115,000 shares of common stock with an aggregate market value of $3,193,550. The securities were acquired through the exercise of stock options, with payment made in cash. The filing also notes that the shares are to be sold via Morgan Stanley Smith Barney LLC on NASDAQ.
Capricor (CAPR) EVP and General Counsel exercises options for 2,500 shares
Capricor Therapeutics' EVP and General Counsel, Karen Krasney, exercised stock options to purchase 2,500 shares of common stock at $1.39 per share. These options were granted in 2017 and adjusted for a reverse stock split and reprice. Following this transaction, Krasney directly holds 30,547 shares of Capricor common stock.
Capricor Therapeutics (CAPR) reports positive phase 3 HOPE-3 data and $318M 2025 cash balance
Capricor Therapeutics announced positive topline results from its Phase 3 HOPE-3 clinical trial of CAP-1002 for Duchenne muscular dystrophy. The trial met its primary and key secondary endpoints, showing improvement in patient function. The company also projects a strong cash and cash equivalents balance of $318 million by the end of 2025.
Technical Reactions to CAPR Trends in Macro Strategies
This article provides a technical analysis of Capricor Therapeutics Inc. (NASDAQ: CAPR), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, and notes a positive sentiment prevailing. The analysis identifies key support and resistance levels, emphasizing an exceptional risk-reward setup.
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) added to S&P Biotechnology Select Industry Index
Capricor Therapeutics, Inc. (NasdaqGS:CAPR) has been added to the S&P Biotechnology Select Industry Index. The company is focused on developing cell and exosome-based therapeutics for rare diseases, with its lead product candidate, CAP-1002, in Phase 3 clinical development for Duchenne muscular dystrophy (DMD). The article also notes recent news including Q4 2025 earnings results and regulatory updates regarding its Deramiocel BLA.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Moderate Buy" from Analysts
Capricor Therapeutics (NASDAQ:CAPR) has received an average rating of "Moderate Buy" from ten analysts, with nine issuing buy ratings and one a sell. The average 1-year price target is $46.09, with some analysts setting targets as high as $62. Despite missing recent EPS estimates, institutional investors have increased their holdings, and the company focuses on developing cell and exosome-based therapeutics.
Why Capricor Therapeutics (CAPR) Is Down 8.0% After FDA Resumes Deramiocel Review And Phase 3 Update
Capricor Therapeutics (CAPR) saw an 8.0% drop despite the FDA resuming its review of Deramiocel's Biologics License Application for Duchenne cardiomyopathy, setting an August 22, 2026 action date. The company reported a wider net loss of US$105.04 million for the full year 2025. This development, coupled with positive new Phase 3 HOPE-3 data, shifts Capricor's investment outlook, though funding needs and dilution risks remain a concern due to continued losses.
Why Capricor Therapeutics (CAPR) Is Down 8.0% After FDA Resumes Deramiocel Review And Phase 3 Update
Capricor Therapeutics (CAPR) stock dropped 8.0% after the FDA resumed its Deramiocel review and updated on Phase 3 data, despite the positive step of an August 22, 2026 action date for potential approval. The company reported a wider net loss of US$105.04 million for the full year, indicating ongoing funding needs and dilution risk. While analysts project significant revenue growth and a strong upside to its current price by 2028, investor focus remains on the balance between promising clinical data and financial challenges.
Capricor Therapeutics (CAPR) reports positive phase 3 HOPE-3 data and $318M 2025 cash balance
Capricor Therapeutics (CAPR) has reported positive phase 3 HOPE-3 data. The company also announced a projected cash balance of $318 million by 2025. This news suggests a strong financial position following positive clinical trial results.
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance
Capricor Therapeutics (CAPR) announced positive new late-breaking data from its Phase 3 HOPE-3 clinical trial, showing that Deramiocel significantly improves cardiac function and slows disease progression in Duchenne muscular dystrophy patients. The therapy has received special designations and is currently under FDA review with a PDUFA target action date of August 22 for potential commercialization in the US market. The company also highlighted a projected $318 million cash balance for 2025.
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise
Capricor Therapeutics opened with a significant 10.29% gain, vastly outperforming the S&P 500's 0.83% rise, and has shown a strong 21.6% increase over the past month. Despite this recent positive movement and bullish technical indicators on weekly and monthly charts, the company faces substantial financial challenges, having reported negative results for four consecutive quarters with significant losses and a high price-to-book ratio. Market observers continue to focus on its performance as it navigates these complexities.
CAPR SEC Filings - Capricor Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Capricor Therapeutics Inc. (CAPR) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. It serves as a crucial resource for investors to understand the company's financial health, regulatory milestones, and significant corporate events, offering AI-powered summaries to simplify complex document content. Recent filings highlight Capricor's financial results and material developments, focusing on its Deramiocel therapy for Duchenne muscular dystrophy.
Capricor Therapeutics 2025 10-K: Revenue $0, EPS $(2.26)
Capricor Therapeutics reported zero revenue for 2025, a significant drop from $22.27 million in 2024, and a net loss per share of $(2.26). This financial performance reflects increased spending on development, manufacturing, and administrative activities in anticipation of a potential commercial launch, particularly with their BLA for Deramiocel under FDA review. Despite the financial losses, the company made progress in regulatory milestones, clinical programs, commercial partnerships, and R&D/manufacturing scale-up.
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance
Capricor Therapeutics announced positive late-breaking data from its Phase 3 HOPE-3 clinical trial for Duchenne muscular dystrophy, showing reduced myocardial fibrosis and slowed disease progression. The therapy, Deramiocel, has a PDUFA target action date of August 22 for FDA approval and has received Orphan Drug and Regenerative Medicine Advanced Therapy status, positioning the company for potential commercialization. An advertisement for an AI stock report is also included, claiming significant upside potential for a different company.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript
Capricor Therapeutics, Inc. discussed their Q4 2025 earnings and provided updates on garamycil's potential approval for Duchenne muscular dystrophy (DMD). The FDA accepted their biologics license application (BLA) resubmission with a PDUFA target action date of August 22, 2026. The company highlighted strong HOPE-3 trial data showing efficacy in both skeletal and cardiac muscle function and is preparing for commercial launch and manufacturing expansion.
A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data
Capricor Therapeutics (CAPR) is under active review by the FDA for its Deramiocel treatment, backed by new HOPE-3 Phase 3 data for Duchenne muscular dystrophy cardiomyopathy. Despite recent strong stock performance and a reported 90% discount to one intrinsic value estimate, the article presents mixed valuation signals. While a discounted cash flow model suggests deep undervaluation at $312.65 relative to the current $30.50 price, traditional metrics like a high P/B ratio (20.9x vs. 2.6x industry average) indicate it might be expensive.
A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data
Capricor Therapeutics (CAPR) is under renewed scrutiny following the FDA's resumption of Deramiocel review, supported by new HOPE-3 data. While the stock has seen significant gains over the past year, with a reported 90% discount to one intrinsic value estimate, investors are debating whether it's truly undervalued or if future growth is already priced in. Traditional metrics like P/B ratio suggest it's expensive, contrasting with a discounted cash flow model that indicates deep undervaluation.
Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative
Capricor Therapeutics (CAPR) reported a significant US$50 million net loss in the first half of FY 2025 with zero revenue, intensifying concerns about its cash burn. While analysts project strong revenue and earnings growth leading to profitability within three years, the company's widening losses and high valuation multiples relative to peers raise questions about execution risk and current fundamentals. Investors are weighing the large projected upside from valuation models against the current financial performance and high premium paid for a loss-making business.
Capricor (NASDAQ: CAPR) details 2025 loss and Deramiocel progress
Capricor Therapeutics reported a significant net loss of $105.0 million in 2025 due to increased operating expenses and the absence of prior collaboration revenues. Despite this, the company's cash reserves rose to $318.1 million, expected to fund operations through 2027. This financial position supports the ongoing FDA review of its lead Duchenne muscular dystrophy therapy, Deramiocel, which has a PDUFA target action date of August 22, 2026.
Capricor Therapeutics, Inc. Q4 2025 earnings preview
This article provides a Q4 2025 earnings preview for Capricor Therapeutics, Inc. The content is concise and directly addresses the upcoming financial report.
Capricor: Q4 Earnings Snapshot
Capricor Therapeutics Inc. announced a significant loss in its fourth quarter, reporting $30.2 million, or 62 cents per share. This performance fell short of Wall Street expectations, which anticipated a loss of 51 cents per share. The company's total loss for the year amounted to $105 million, or $2.26 per share.
Duchenne trial drug from Capricor slows key task decline 83%
Capricor Therapeutics reported its Q4 and full-year 2025 financial results, highlighting significant progress with Deramiocel for Duchenne muscular dystrophy. The Biologics License Application (BLA) for Deramiocel is under FDA review with a PDUFA target action date of August 22, 2026, following positive Phase 3 HOPE-3 trial results that met primary and key cardiac endpoints. The company also announced late-breaking data showing an 83% slowing of disease progression in a daily activity task and confirmed a strong cash position of $318.1 million, providing a runway through 2027.
Is It Too Late To Consider Capricor Therapeutics (CAPR) After Strong Multi Year Share Gains?
Capricor Therapeutics (CAPR) has seen significant share gains, with a 156.8% return over the last year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 87.3% at $33.57 per share, estimating an intrinsic value of $264.99. However, its Price-to-Book (P/B) ratio of 20.70x is significantly higher than the biotech industry average, indicating it is overvalued by this metric.
CAPR Stock In Focus: Capricor Says Phase 3 DMD Trial Shows Cardiac Improvement With Deramiocel
Capricor Therapeutics announced new data from its Phase 3 HOPE-3 trial for Deramiocel, showing improved heart function in Duchenne muscular dystrophy (DMD) patients. The cardiac MRI results presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference indicated a significant reduction in fibrosis and a 3.3 percentage-point improvement in left ventricular ejection fraction for patients with baseline cardiomyopathy. The company's Biologics License Application for Deramiocel is currently under FDA review, with a decision expected by August 22, 2026.
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data
Capricor Therapeutics announced new functional outcomes data from its Phase 3 HOPE-3 clinical trial of Deramiocel for Duchenne muscular dystrophy (DMD). The data, presented at the 2026 MDA conference, showed significant functional benefits including reduced progression of myocardial fibrosis, improved cardiac function in patients with cardiomyopathy, and an 83% slowing of disease progression in daily activities. The company's Biologics License Application for Deramiocel is currently under FDA review with a PDUFA target action date of August 22, 2026.
Cell therapy for Duchenne slows key eating task decline by 83%
Capricor Therapeutics announced positive late-breaking Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy, showing significant functional and cardiac benefits. Key findings include an 83% slower progression in a key eating task, reduced myocardial fibrosis, and improved LVEF in patients with baseline cardiomyopathy. A Biologics License Application for Deramiocel is currently under FDA review with a PDUFA date of August 22, 2026.
Capricor Therapeutics falls on Q4 earnings miss
Capricor Therapeutics reported a fourth-quarter loss of $0.62 per share, missing analyst estimates, and zero revenue due to fully recognized milestone payments from a distribution agreement. The company's net loss widened significantly compared to the previous year, driven by increased operating expenses related to commercial preparation activities. Despite the financial miss, Capricor's CEO highlighted regulatory and clinical momentum for their drug Deramiocel, which is currently under FDA review.
Why Capricor Therapeutics (CAPR) Is Up 29.3% After FDA Resumes Review of Deramiocel BLA
Capricor Therapeutics saw a significant stock increase after the FDA resumed its review of the Biologics License Application for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy cardiomyopathy. The FDA assigned a Class 2 resubmission with a PDUFA target action date of August 22, 2026, extending the regulatory timeline. This renewed review, along with existing regulatory designations and a commercialization agreement with Nippon Shinyaku, impacts investor perception of Capricor's market entry potential, though funding needs and single-asset reliance remain key risks.
H.C. Wainwright Maintains Buy on Capricor Therapeutics, Inc. (CAPR) Mar 2026
H.C. Wainwright has maintained its Buy rating on Capricor Therapeutics, Inc. (CAPR) with a $60 price target. This signal of confidence comes despite a recent -4.49% stock movement and highlights the biotech company's development roadmap. Meyka AI gives CAPR a B+ grade, acknowledging the positive analyst tilt but also flagging the risk of concentrated coverage.
Why Capricor Therapeutics (CAPR) Is Up 29.3% After FDA Resumes Review of Deramiocel BLA
Capricor Therapeutics (CAPR) saw its stock jump after the FDA resumed the Biologics License Application (BLA) review for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy cardiomyopathy. The FDA assigned a Class 2 resubmission with a PDUFA target action date of August 22, 2026. This development significantly impacts Capricor's investment narrative, extending the timeline for potential market entry and highlighting the continued reliance on this single asset for the company's future revenue.
Capricor Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Capricor Therapeutics Inc (CAPR) is projected to report a loss of 54 cents per share. This information comes ahead of the company's earnings announcement. The report is categorized as an earnings preview.
Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright
HC Wainwright has reiterated a "Buy" rating for Capricor Therapeutics (NASDAQ:CAPR), setting a price target of $60, which implies a 70.07% upside. The biotechnology company currently holds a "Moderate Buy" consensus from analysts, with an average target price of $40.82. Institutional investors have also increased their holdings in CAPR, which saw its stock jump 15.2% on heavy volume.
Capricor Therapeutics Sees Surge in Trading Volume
Capricor Therapeutics (NASDAQ:CAPR) experienced a nearly 15% surge in its share price and a 95% increase in trading volume on Tuesday, signaling heightened investor interest in the company's cell and exosome-based therapies. Despite mixed ratings from research firms, analysts maintain a "Moderate Buy" consensus with a target price of $40.82. The increased attention is likely due to the progress of its lead candidate, CAP-1002, for Duchenne muscular dystrophy and COVID-19-related heart injury.
